7th CKD (Chronic Kidney Disease Drug Development) Summit

Topics

• Where is the Landscape Heading in Terms of Acceptable Surrogate Endpoints in CKD?
• Varied Heterogeneity Across CKD Populations to Innovate More Precise & Subgroup-Specific Treatments
• Biomarker Innovation to Facilitate Early Phase CKD Trials
• Late Phase Endpoints & Regulatory Acceptance
• Developing Next-Generation Preclinical Models to Recapitulate Human Renal Function & Pathophysiology
• Novel Innovation in Early-Phase Clinical Evaluation of CKD Candidates
• Enhancing Trial Design in Response to the Expanding CKD Market
• The Journey Towards More Personalized Therapies for Rare & Common Kidney Disease Patients
• Combining Patient Insight & Fostering Diversity in Renal Trials
• Availability of Advancing Technologies to Identify New Targets
• Clinical Progress in Regenerative Medicine: Striving Towards a One-Dose Cure for CKD
• Translating New CKD Therapies into Clinical Practice Guidelines in a Rapidly Changing Landscape
• Translating Advanced Drug Delivery Systems to the Clinic for Safe & Specific Renal Targeting
• Current & Potential Immune Targets in Clinical Development for Kidney Disease
• Optimizing Real-World Evidence to Supplement Clinical Studies & Maximizing Payer Support
• What’s Next for CKD Drug Development?